Transcriptomic Profiling of the Four Adenosine Receptors in Human Leukocytes of Heart Failure Patients

Table 1

Clinical and biochemical characteristics of heart failure patients.

	Patients; NYHA I-II; (𝑛=9)	Patients; NYHA III-IV; (𝑛=14)	𝑃
Age, yrs	54±4	53±2	0.801
Male, 𝑛 (%)	9 (100)	7 (50)	0.019
BMI, kg/m^2	26±3	26±1	0.557
Diabetes, 𝑛 (%)	1 (11)	3 (21)	1.000
Etiology, 𝑛 (%)			0.611
IDC	8 (89)	10 (71)
IHD	1 (11)	4 (29)
LVEDV, mL	180±33	268±29	0.027
LVESV, mL	128±29	202±24	0.055
LVEF, %	33±4	26±2	0.159
MID, 𝑛 (%)			0.074
0	1 (11)	—
1+	5 (56)	2 (14)
2+	2 (22)	8 (57)
3+	1 (11)	4 (29)
4+	—	—
LA area, cm^2	20±2	39±7	0.007
Therapy, 𝑛 (%)
ACEi	7 (79)	8 (57)	0.400
β-Blocker	9 (100)	14 (100)	1.000
Statin	4 (44)	7 (50)	1.000
Antiplatelets	6 (67)	8 (57)	1.000
Diuretic	7 (78)	14 (100)	0.142
C-reactive protein, mg/dL	0.3±0.1	0.8±0.3	0.410

Data are expressed as mean and SE or frequency (percentage).
BMI: body mass index; IDC: idiopathic dilated cardiomyopathy; IHD: ischemic heart disease; NYHA: New York Heart Classification; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; MID: mitral insufficiency grade; LA: left atrium; ACEi: angiotensin converting enzyme inhibitor.